Company
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Apellis Pharmaceuticals Inc is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases.
4 stories
Apellis Pharmaceuticals advances as US regulator approves new drug application (NDA) amendment for geographic atrophy (GA) therapy
GA is a leading cause of blindness that impacts more than five million people worldwide, including one million in the US